Molecular testing tools, including tumor sequencing and increasingly sensitive diagnostics, are leveling up oncology by enabling precise, personalized cancer treatment. Clinicians can now detect circulating tumor DNA, assess patients' cancer risk, monitor for resistance mutations, and adjust treatments in real time.

Dr. Alec Kimmelman, director of the Perlmutter Cancer Center, discusses how NYU Langone’s integrated infrastructure enhances data-driven clinical decisions and contributes to groundbreaking cancer research.